Počet záznamů: 1

Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease

SYSNO ASEP	0563725
Druh ASEP	J - Článek v odborném periodiku
Zařazení RIV	J - Článek v odborném periodiku
Poddruh J	Článek ve WOS
Název	Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
Tvůrce(i)	Hojná, Silvie (FGU-C)_{RID, ORCID} Kotsaridou, Zoe (FGU-C) Vaňourková, Z. (CZ) Rauchová, Hana (FGU-C)_{RID, ORCID} Behuliak, Michal (FGU-C)_{RID, ORCID} Kujal, P. (CZ) Kadlecová, Michaela (FGU-C)_RID Zicha, Josef (FGU-C)_{RID, ORCID, SAI} Vaněčková, Ivana (FGU-C)_{RID, ORCID}
Číslo článku	2509
Zdroj.dok.	Biomedicines. - : MDPI Roč. 10, č. 10 (2022)
Poč.str.	14 s.
Jazyk dok.	eng - angličtina
Země vyd.	CH - Švýcarsko
Klíč. slova	SGLT-2 inhibition ; proteinuria ; uninephrectomized salt-loaded ; two-kidney ; one-clip hypertension ; fawn-hooded hypertensive rat
Obor OECD	Physiology (including cytology)
CEP	GA19-06199S GA ČR - Grantová agentura ČR
Způsob publikování	Open access
Institucionální podpora	FGU-C - RVO:67985823
UT WOS	000872279500001
EID SCOPUS	85140611804
DOI	10.3390/biomedicines10102509
Anotace	Gliflozins (sodium-glucose transporter-2 inhibitors) exhibited renoprotective effects not only in diabetic but also in non-diabetic patients with chronic kidney disease (CKD). Controversial results were reported in experimental non-diabetic models of CKD. Therefore, we examined empagliflozin effects in three CKD models, namely, in fawn-hooded hypertensive (FHH) rats, uninephrectomized salt-loaded (UNX + HS) rats, and in rats with Goldblatt hypertension (two-kidney, one-clip 2K1C) that were either untreated or treated with empagliflozin (10 mg/kg/day) for eight weeks. Plethysmography blood pressure (BP) was recorded weekly, and renal parameters (proteinuria, plasma urea, creatinine clearance, and sodium excretion) were analyzed three times during the experiment. At the end of the study, blood pressure was also measured directly. Markers of oxidative stress (TBARS) and inflammation (MCP-1) were analyzed in kidney and plasma, respectively. Body weight and visceral adiposity were reduced by empagliflozin in FHH rats, without a significant effect on BP. Experimentally induced CKD (UNX + HS and 2K1C) was associated with a substantial increase in BP and relative heart and kidney weights. Empagliflozin influenced neither visceral adiposity nor BP in these two models. Although empagliflozin increased sodium excretion, suggesting effective SGLT-2 inhibition, it did not affect diuresis in any experimental model. Unexpectedly, empagliflozin did not provide renoprotection because proteinuria, plasma urea, and plasma creatinine were not lowered by empagliflozin treatment in all three CKD models. In line with these results, empagliflozin treatment did not decrease TBARS or MCP-1 levels in either model. In conclusion, empagliflozin did not provide the expected beneficial effects on kidney function in experimental models of CKD.
Pracoviště	Fyziologický ústav
Kontakt	Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400
Rok sběru	2023
Elektronická adresa	https://www.mdpi.com/2227-9059/10/10/2509

Počet záznamů: 1